Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of IMD1828 in advanced solid tumors
CTR20262487Phase 2Active
- Sponsor
- Inmed Medical Technology
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IMD1828 in Nonhematologic neoplasms, ovarian cancer, endometrial cancer (EC), germ cell tumor (GCT), non-small cell lung cancer (NSCLC), sponsored by Inmed Medical Technology. Started Jul 2026; status: active.
02
Drugs
IMD1828
03
Conditions
Nonhematologic neoplasmsovarian cancerendometrial cancer (EC)germ cell tumor (GCT)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262487.